WESTMINSTER, Colo.--(BUSINESS WIRE)--Jul. 23, 2009-- Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced the launch of a new website, www.focusonptcl.com, dedicated to peripheral T-cell lymphoma (PTCL). This on-line resource is designed to provide information to patients and caregivers to aide in the understanding of PTCL. Healthcare providers will be able to utilize this resource to obtain clinical information, including staging and diagnosis.

“We are delighted to see a dedicated educational effort on PTCL for patients and healthcare providers. PTCL is a subtype of non-Hodgkin’s lymphoma and has a unique presentation and prognosis,” comments Judy Jones, LPC, president of the Cutaneous Lymphoma Foundation. “The new website, www.focusonptcl.com, fills a void and has compiled a wealth of information for patients and physicians. We encourage patients and physicians alike to visit the site for information about the disease, diagnosis and various treatment options.”

PTCL: A significant unmet need

• PTCL comprises a heterogeneous group of aggressive mature T- and NK-cell lymphomas that accounts for approximately 10% to 15% of new non-Hodgkin’s lymphoma (NHL) cases per year in the U.S.
• The American Cancer Society estimates that approximately 66,000 new cases of NHL will be diagnosed in the U.S. in 2009
• No pharmaceutical agents are currently FDA-approved for use in the treatment of either first-line or relapsed or refractory PTCL
• Due to the aggressive nature of the disease, a significant number of patients relapse or become refractory after initial treatment

This educational resource compiles important information on the diagnosis and treatment of PTCL into a web-based knowledge center. The site has been designed to provide the most up-to-date medical information to physicians and includes important information about the disease state and potential treatments for patients, their families and caregivers. The Company intends to maintain the website to ensure that up-to-date information on PTCL is available to the lymphoma community.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. The Company’s product candidate, pralatrexate, is a selective antifolate designed to accumulate preferentially in cancer cells. The Company recently announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma for priority review and established a Prescription Drug User Fee Act date of September 24, 2009 for a decision regarding approval of the NDA. In addition, pralatrexate is being evaluated in patients with non-small cell lung cancer, bladder cancer and a range of lymphoma sub-types. Allos retains exclusive worldwide rights to pralatrexate for all indications. The Company is headquartered in Westminster, CO. For more information about Allos, visit www.allos.com.

Safe Harbor Statement

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “continue,” and other similar terminology or the negative of these terms, but their absence does not mean that a particular statement is not forward-looking. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. Information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.

Source: Allos Therapeutics, Inc.

Allos Therapeutics, Inc.
Monique Greer, 720-540-5268
mgreer@allos.com